subject area of

• A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma  Academic Article
• A Long, Naturally Presented Immunodominant Epitope from NY-ESO-1 Tumor Antigen: Implications for Cancer Vaccine Design  Academic Article
• A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35  Academic Article
• A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant  Academic Article
• Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells  Academic Article
• An HLA-A2 polyepitope vaccine for melanoma immunotherapy  Academic Article
• Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guerin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma  Academic Article
• Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients  Academic Article
• CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients  Academic Article
• Cancer vaccines: Where are we going?  Academic Article
• Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells  Academic Article
• Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination  Academic Article
• Clinical promise of tumour immunology  Academic Article
• Current Status of Veterinary Vaccines  Academic Article
• Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens  Academic Article
• Directions in the immune targeting of cancer: Lessons learned from the cancer‐testis Ag NY‐ESO‐1  Academic Article
• Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting  Academic Article
• Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1  Academic Article
• Evolving role of tumor antigens for future melanoma therapies  Academic Article
• Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients’ sera using short overlapping peptides and full-length recombinant protein  Academic Article
• Functional and Structural Characteristics of NY-ESO-1-related HLA A2-restricted Epitopes and the Design of a Novel Immunogenic Analogue  Academic Article
• HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan  Academic Article
• Humoral immune responses in patients vaccinated with 1–146 HER2 protein complexed with cholesteryl pullulan nanogel  Academic Article
• ISCOMATRIX Adjuvant Induces Efficient Cross-Presentation of Tumor Antigen by Dendritic Cells via Rapid Cytosolic Antigen Delivery and Processing via Tripeptidyl Peptidase II  Academic Article
• Immunodominance and Immunodomination: Critical Factors in Developing Effective CD8+ T‐Cell–Based Cancer Vaccines  Book
• Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™  Academic Article
• Immunotherapy of melanoma: Targeting defined antigens  Academic Article
• Influenza A Infection Enhances Cross-Priming of CD8+T Cells to Cell-Associated Antigens in a TLR7- and Type I IFN-Dependent Fashion  Academic Article
• Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy  Academic Article
• Lentivector immunization induces tumor antigen‐specific B and T cell responsesin vivo  Academic Article
• Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX (TM) vaccine in patients with advanced melanoma  Academic Article
• Mannan-MUC1-Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma  Academic Article
• Melanoma vaccines: developments over the past 10 years  Academic Article
• NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors  Academic Article
• Optimal conditions required for influenza A infection‐enhanced cross‐priming of CD8 + T cells specific to cell‐associated antigens  Academic Article
• Perspective: cancer vaccines in the era of immune checkpoint blockade  Academic Article
• Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery  Academic Article
• Rational approaches to human cancer immunotherapy  Academic Article
• Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis  Academic Article
• Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans  Academic Article
• Recombinant NY‐ESO‐1 Cancer Antigen: Production and Purification under cGMP Conditions  Academic Article
• Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma  Academic Article
• T Cell Determinants Incorporating β-Amino Acid Residues Are Protease Resistant and Remain Immunogenic In Vivo  Academic Article
• T cells recognizing a 11mer influenza peptide complexed to H-2D(b) show promiscuity for peptide length  Academic Article
• Targeted therapy of renal cell carcinoma: Synergistic activity of cG250-TNF and IFNg  Academic Article
• Telomerase in cancer immunotherapy  Academic Article
• The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization  Academic Article
• The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning.  Academic Article
• The immune suppressive function of transforming growth factor-β (TGF-β) in human diseases  Academic Article
• The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.  Academic Article
• The therapeutic benefit of bacterial membrane vesicles  Academic Article
• Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1  Academic Article
• Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery  Academic Article
• Tumor-Specific T-cell Help Is Associated with Improved Survival in Melanoma  Editorial Article
• Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.  Academic Article